What the trial was testing
The trial enrolled 55 patients with stroke. The study was sponsored by University of Cincinnati and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
High-intensity walking improved distance walked by 71 meters versus 27 meters with moderate exercise after 12 weeks.
JAMA neurology · 2023 · NCT03760016
These findings — that high-intensity bursts of walking improved distance more than steady moderate walking — were published in the JAMA neurology and represent the headline result of the study.
Researchers tracked outcomes across 55 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with stroke, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This study showed that vigorous walking exercise helps stroke survivors walk farther than moderate exercise, but you need at least 12 weeks to see the best results. Talk to your doctor or physical therapist about whether high-intensity walking training is right for you. These are standard rehabilitation approaches your care team can guide you on.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open stroke trials
Body Composition and Acute Stroke
Body composition appears to be a prognostic factor for the severity and functional outcome of stroke patients. In this study the prognostic value of two bioimpedance parameters will be studied (skeletal mass index and phase angle) and two temporal muscle measurements (thickness and surface area) to predict the functional outcome of patients at discharge and at 6 months
Intracerebral Autologous Stem Cell Therapy for Chronic Stroke Patients
The goal of this clinical trial is to evaluate if autologous mesenchymal stem cell (HUNS001-01) transplantation therapy can provide neurological recovery in patients with chronic stage of stroke resulting in moderate to severe neurological sequelae. The main questions it aims to answer are: Can HUNS001-01 intracerebral transplantation demonstrate improvement in the mRS of disability for 1 year after intervention? Can HUNS001-01 intracerebral transplantation can be performed without any adverse events for 1 year after intervention? Participants will receive the below interventions. * Screening for the eligibility to enroll the clinical trial (interview, blood test, imaging) * Harvest of platelet concentrates (PC) * Harvest of bone marrows (BM) * Receive intracerebral transplantation surgery of HUNS001-01 * Post-operative rehabilitation * Follow-up studies (until 1 year or termination of the trial)